

27 December 2023

ASX Announcement

Firebrick Closes AAT Appeal

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) announces that on 22 December 2023, the Company withdrew its appeal with the Administrative Appeals Tribunal (**AAT**) against the TGA's decision not to approve Nasodine® Nasal Spray (**Nasodine**). The AAT has subsequently confirmed that the appeal has been closed.

The Company considered the significant distraction and legal costs associated with proceeding to a formal Hearing (previously scheduled for May 2024) in its decision to withdraw the Appeal, especially given the Company's recently announced strategy to focus its operational attention and funds on international markets for Nasodine.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company with the mission to develop and commercialise a povidone-iodine nasal spray. The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the US, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com